ANGPTL2 has been shown to be increasingly methylated in ovarian cancer [34] and myelodysplastic syndrome [35], while ANGPTL2 promoter methylation is decreased in osteosarcoma [36]. This evidence concerns the gene ANGPTL2 and osteosarcoma.